Prime Editing

Overview

Third-generation gene editing platform that makes precise edits without double-strand DNA breaks; capable of transitions, transversions, insertions, and deletions; first published in 2019 and commercialized through Prime Medicine. Prime editing is described as a third-generation gene editing technology first published at the end of 2019, developed in David Liu's laboratory by Andrew Anzalone, that makes no double-strand DNA breaks and is capable of transitions, transversions, insertions, and deletions. Prime editing's versatility enabled Prime Medicine to begin with 18 pipeline programs at founding, then generate 153 additional program concepts during a single indications day, spanning diverse therapeutic areas. (Segment 2 (05:00-10:00))